Bavarian Nordic on vaccine candidate: Preclinical data indicates broad protection

Preclinical data on Bavarian Nordic's covid-19 vaccine candidate indicates broad protection, the company reports on Thursday.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

In a press release on Thursday morning, Danish biotech company Bavarian Nordic states that new preclinical trial data indicates that the firm's vaccine candidate against covid-19 also has the ability to induce a high number of neutralizing antibodies against covid variants and mutations.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading